Literature DB >> 1637660

Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.

L Lemaire1, M C Malet-Martino, M de Forni, R Martino, B Lasserre.   

Abstract

The cardiotoxicity of 5-fluorouracil (FU) was attributed to impurities present in the injected vials. One of these impurities was identified as fluoroacetaldehyde which is metabolised by isolated perfused rabbit hearts into fluoroacetate (FAC), a highly cardiotoxic compound. FAC was also detected in the urine of patients treated with FU. These impurities were found to be degradation products of FU that are formed in the basic medium employed to dissolve this compound. To avoid chemical degradation of this antineoplastic drug, the solution of FU that will be injected should be prepared immediately before use.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1637660      PMCID： PMC1977901          DOI： 10.1038/bjc.1992.227

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  25 in total

Review 1.  5-Fluorouracil cardiotoxicity: a critical review.

Authors:  W J Gradishar; E E Vokes
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

2.  F Nuclear Magnetic Resonance Analysis of 5-Fluorouracil Metabolism in Four Differently Pigmented Strains of Nectria haematococca.

Authors:  D Parisot; M C Malet-Martino; R Martino; P Crasnier
Journal:  Appl Environ Microbiol       Date:  1991-12       Impact factor: 4.792

Review 3.  Uses and limitations of nuclear magnetic resonance (NMR) spectroscopy in clinical pharmacokinetics.

Authors:  M C Malet-Martino; R Martino
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.

Authors:  S Rezkalla; R A Kloner; J Ensley; M al-Sarraf; S Revels; A Olivenstein; S Bhasin; S Kerpel-Fronious; Z G Turi
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

5.  Kinetics and mechanisms of hydrolysis of 5-halouracils.

Authors:  E R Garrett; H J Nestler; A Somodi
Journal:  J Org Chem       Date:  1968-09       Impact factor: 4.354

Review 6.  [Fluorine-19 nuclear magnetic resonance spectroscopy: a privileged tool for the study of the metabolism and pharmacokinetics of fluoropyrimidines].

Authors:  M C Malet-Martino; R Martino; J P Armand
Journal:  Bull Cancer       Date:  1990       Impact factor: 1.276

7.  Enzymatic defluorination and metabolism of fluoroacetate, fluoroacetamide, fluoroethanol, and (-)-erythro-fluorocitrate in rats and mice examined by 19F and 13C NMR.

Authors:  B Tecle; J E Casida
Journal:  Chem Res Toxicol       Date:  1989 Nov-Dec       Impact factor: 3.739

8.  Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry.

Authors:  M C Malet-Martino; J P Armand; A Lopez; J Bernadou; J P Béteille; M Bon; R Martino
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

9.  19F nuclear magnetic resonance analysis of the carbamate reaction of alpha-fluoro-beta-alanine (FBAL), the major catabolite of fluoropyrimidines. Application to FBAL carbamate determination in body fluids of patients treated with 5'-deoxy-5-fluorouridine.

Authors:  R Martino; M C Malet-Martino; C Vialaneix; A Lopez; M Bon
Journal:  Drug Metab Dispos       Date:  1987 Nov-Dec       Impact factor: 3.922

10.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.

Authors:  W E Hull; R E Port; R Herrmann; B Britsch; W Kunz
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701
View more
  10 in total

Review 1.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 2.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 3.  Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.

Authors:  M T Paff; D P Baccanari; S T Davis; S Cao; R L Tansik; Y M Rustum; T Spector
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Capecitabine-induced cardiotoxicity: case report and review of the literature.

Authors:  C Ang; M Kornbluth; M P Thirlwell; R D Rajan
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

Review 5.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

6.  Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.

Authors:  C H Köhne; P Thuss-Patience; M Friedrich; P T Daniel; A Kretzschmar; T Benter; B Bauer; R Dietz; B Dörken
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.

Authors:  M Arellano; M Malet-Martino; R Martino; P Gires
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

Review 8.  A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity.

Authors:  Anne Polk; Kirsten Vistisen; Merete Vaage-Nilsen; Dorte L Nielsen
Journal:  BMC Pharmacol Toxicol       Date:  2014-09-04       Impact factor: 2.483

9.  On Complex Formation between 5-Fluorouracil and β-Cyclodextrin in Solution and in the Solid State: IR Markers and Detection of Short-Lived Complexes by Diffusion NMR.

Authors:  Daria L Melnikova; Zilya F Badrieva; Mikhail A Kostin; Corina Maller; Monika Stas; Aneta Buczek; Malgorzata A Broda; Teobald Kupka; Anne-Marie Kelterer; Peter M Tolstoy; Vladimir D Skirda
Journal:  Molecules       Date:  2020-12-03       Impact factor: 4.411

10.  5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.

Authors:  M Arellano; M Malet-Martino; R Martino; T Spector
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.